Will invest US$200m over the next few years
Amgen is to build a new manufacturing facility in the Tuas Biomedical Park area of Singapore.
The US biotechnology firm plans to invest around US$200m over the next few years to build the facility, which will initially focus on expanding manufacturing capability for monoclonal antibodies. The plant will be capable of manufacturing both clinical and commercial products.
‘Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,’ said Madhu Balachandran, executive vice president of operations at Amgen.
Construction will begin in the next few months.
The facility will be staffed with new and experienced staff and Amgen says it is currently working with local universities to recruit for a number of positions in manufacturing and quality.